1.71
+0.07(+4.27%)
Currency In USD
| Previous Close | 1.64 |
| Open | 1.65 |
| Day High | 1.71 |
| Day Low | 1.62 |
| 52-Week High | 22.99 |
| 52-Week Low | 1.39 |
| Volume | 464,356 |
| Average Volume | 1.54M |
| Market Cap | 27.79M |
| PE | -0.32 |
| EPS | -5.36 |
| Moving Average 50 Days | 2.03 |
| Moving Average 200 Days | 3.59 |
| Change | 0.07 |
If you invested $1000 in Jasper Therapeutics, Inc. (JSPR) since IPO date, it would be worth $17.41 as of December 17, 2025 at a share price of $1.71. Whereas If you bought $1000 worth of Jasper Therapeutics, Inc. (JSPR) shares 3 years ago, it would be worth $297.91 as of December 17, 2025 at a share price of $1.71.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation
GlobeNewswire Inc.
Dec 02, 2025 12:00 PM GMT
Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further development of briq
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation
GlobeNewswire Inc.
Dec 01, 2025 9:30 PM GMT
Webinar to be held Tuesday, December 2nd, at 8:00 am ETREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briqui
Jasper Therapeutics Announces Pricing of $30 Million Public Offering of Common Stock, Pre-Funded Warrants and Common Warrants
GlobeNewswire Inc.
Sep 19, 2025 4:07 AM GMT
REDWOOD CITY, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (“Jasper”), a clinical-stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting KIT (CD117) to address ma